Good News on GLP-1 Weight-Loss Medications: Some Patients Maintain Weight Loss After Stopping Treatment
For years, one of the most common criticisms of GLP-1 weight-loss medications such as Ozempic®, Wegovy®, Mounjaro®, and Zepbound® has been the belief that once patients stop these medications, all the lost weight inevitably comes back.
While weight regain does occur for some patients, new real-world data suggest that this outcome is not universal—and that durable weight loss may be achievable for many patients with proper medical support.
What the New Data Shows
An analysis shared with Reuters by researchers from the U.S. data analytics firm nference examined real-world outcomes among patients treated at large academic medical centres across the United States.
Using artificial intelligence, researchers analyzed:
- 14 million physician notes
- 15 million clinical data entries
- Over 135,000 patients treated with a single GLP-1 medication over one year
Their findings challenge the assumption that stopping GLP-1 therapy automatically leads to rapid weight regain.
Key Findings at Six Months After Stopping GLP-1 Therapy
Among patients who discontinued tirzepatide (Mounjaro®, Zepbound®):
28% regained weight
36% maintained their weight loss
36% continued to lose weight
Among patients who discontinued semaglutide (Ozempic®, Wegovy®):
33% regained weight
32% maintained weight loss
35% continued losing weight
Notably, the median weight change was 0%, suggesting that the “typical” patient stabilized rather than rebounded.
Why This Matters
Clinical trials sponsored by pharmaceutical manufacturers have previously suggested that most patients regain significant weight after stopping GLP-1 drugs. However, clinical trials occur under tightly controlled conditions and may not reflect how medications are used in everyday clinical practice.
As the nference researchers explained, this real-world evidence does not suggest rebound risk disappears—but rather that weight-loss durability is achievable in routine care when patients receive appropriate follow-up and support.
This opens the door to a more nuanced, individualized approach to obesity management, where clinicians can:
- Identify patients who may safely discontinue therapy
- Use intermittent or step-down treatment strategies
- Support long-term metabolic health beyond medication alone
The Role of Lifestyle and Medical Guidance
One of the most important findings was that patients who received exercise counseling after stopping GLP-1 therapy were nearly twice as likely to maintain their weight loss compared with those who did not.
Former FDA Commissioner Dr. David Kessler, who previously used a GLP-1 medication himself, emphasized that long-term success depends on whether patients learn to modify eating patterns and habits while on therapy.
GLP-1 medications reduce appetite and calorie intake—but once the medication is stopped, those effects diminish, making sustained behavior change critical.
Why Primary Care–Led Management Matters
At Orleans Family Health Clinic, we view GLP-1 medications not as a standalone solution, but as one tool within a comprehensive, physician-led obesity and metabolic care plan.
Sustainable outcomes are more likely when patients receive:
- Ongoing medical supervision
- Nutritional and lifestyle counseling
- Monitoring for mental health factors such as anxiety or depression
- Support through medication changes or discontinuation
This study reinforces what family physicians have long understood: long-term success comes from continuity of care, not one-time prescriptions.
Important Limitations to Keep in Mind
The researchers caution that this study:
- Is observational and awaiting peer review
- Does not fully account for all lifestyle or medical variables
- Cannot prove causation
Nevertheless, it offers measured optimism that GLP-1 therapy does not have to be lifelong for every patient.
The Takeaway
GLP-1 medications remain powerful tools for weight management—but their greatest value may be in helping patients build healthier patterns that last beyond the prescription itself.
With structured follow-up, individualized care, and proper guidance, some patients can maintain—or even continue—weight loss after stopping treatment.
If you are considering GLP-1 therapy or wondering how to safely transition off these medications, a primary care–based approach is essential.
Orleans Family Health Clinic is committed to evidence-based, compassionate, and continuous care—supporting patients at every stage of their health journey.
Stay Connected with Orleans Family Health Clinic!
If you found this article helpful, don’t forget to like, share, and Follow to stay up to date on our latest health tips, updates, and wellness advice.
And follow us on social media
Disclaimer: The medical information on this site is provided as an information resource only and is not to be used or relied on for any diagnostic or treatment purposes. This information does not substitute for professional diagnosis and treatment. Please do not initiate, modify, or discontinue any treatment, medication, or supplement solely based on this information. Always seek the advice of your healthcare provider first. Full Disclaimer.
